Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EPS (Weighted Average and Diluted) (2016 - 2025)

Integra Lifesciences Holdings' EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at -$0.02 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 108.0% year-over-year to -$0.02; the TTM value through Dec 2025 reached -$6.74, down 7388.89%, while the annual FY2025 figure was -$6.74, 7388.89% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.02 at Integra Lifesciences Holdings, up from -$0.07 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.63 in Q4 2022 and bottomed at -$6.32 in Q2 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.25 (2023), against an average of -$0.09.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 9511.78% in 2021 before it plummeted 3850.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.53 in 2021, then grew by 18.87% to $0.63 in 2022, then tumbled by 60.32% to $0.25 in 2023, then changed by 0.0% to $0.25 in 2024, then crashed by 108.0% to -$0.02 in 2025.
  • Per Business Quant, the three most recent readings for IART's EPS (Weighted Average and Diluted) are -$0.02 (Q4 2025), -$0.07 (Q3 2025), and -$6.32 (Q2 2025).